Denial of information grossly improper, says CIC

New Delhi : The Central Information Commission (CIC) has called the electronics and information technology ministry’s denial of information about comments related to the public consultation on the Personal Data Protection Bill “grossly improper”.

Information commissioner Vanaja Sarna, in an order dated March 25, directed the concerned officer to revisit the application. It added in case the ministry cannot justify the right grounds to withhold the information, the details should be made public.

The direction is to be complied with within 15 days from the date of receipt of the order.

Digital rights advocacy group Internet Freedom Foundation sought information under the Right To Information (RTI) Act on the consultations conducted before drafting the bill around three years ago. “We will keep persisting for transparency around the Data Bill,” the foundation tweeted on Friday.

A ministry official said they’ll look into the order.

Reference: CIC, Apar Gupta vs CPIO, Department of Electronics & Information Technology (MEITY), New Delhi, File no.: – CIC/MOIAB/A/2019/110785/MOEIT, D/d 25.3.2021

  • Related Posts

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    New Delhi — In a significant move to bring greater transparency and accountability in healthcare delivery, the Centre has directed all states and Union Territories to tighten regulatory oversight within…

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid